Eroglu, ErsanAlgul, SerminKiziltan, RemziKemik, OzgurAltinli, Ediz2026-04-022026-04-0220262667-663X10.4328/ACAM.22524https://hdl.handle.net/123456789/30248https://doi.org/10.4328/ACAM.22524Aim: Whether plasma levels of autotaxin (ATX) and lysophosphatidate (LPA) could be distributed to diagnostic biomarkers for colon cancer is ill-defined. In our study, we appraised the possibility of plasma LPA and ATX as cancer biomarkers. Methods: A total of 90 patients hospitalized at the general surgery clinic with the diagnosis of colon cancer were included in the study. The control group consisted of 50 healthy individuals who had no known disease. There were 30 cases of early-stage (I/II), 50 cases of late-stage (III-IV) colon cancer, and 50 cases of lymph node metastasis (N1/N2). Results: Preoperative serum ATX levels were higher in patients with colon cancer according to the healthy control group (p<0.001). Preoperative serum LPA levels were higher in patients with colon cancer (56.2 +/- 13.06 ng/mL, median: 62 ng/mL, range 23-69.6 ng/mL) according to the healthy control group (8.77 +/- 2.3 ng/mL, median: 9 ng/mL, range 4-12 ng/mL) (p<0.001). The concentration of ATX in the preoperative serum of the patients with Stage T4 (298.57 +/- 19.7 ng/L, median 300 ng/L, with a range of 20-330 ng/L) was significantly higher compared to patients with Stages T1, T2, and T3. The levels of ATX in the serum of the patients with T3 (219.41 +/- 19.7 ng/L, median 200 ng/L, with a range of 180-250 ng/L) were significantly higher compared to the patients with Stages T1 and T2. Conclusion: It appears that our analysis of ATX is to be a useful prognostic marker to predict the survival of patients with colon cancer, along with their response to dissimilar therapeutic agents.eninfo:eu-repo/semantics/openAccessLPAATXColon CancerBiomarkersTNM StagesArticle